Lipoprotein(a), or Lp(a), is a genetically determined particle that raises your risk of heart attack, stroke, and aortic valve disease independently of your regular cholesterol numbers. Unlike LDL, it isn't changed by diet or exercise, which is why the newest guidelines recommend every adult have it checked at least once in their lifetime.
Lp(a) is an LDL-like particle with an extra protein — apolipoprotein(a) — attached to it. That extra protein makes it more likely to promote plaque buildup in arteries and to interfere with the body's own clot-dissolving system. Your Lp(a) level is set almost entirely by your genes; unlike LDL cholesterol, it is not meaningfully affected by diet, exercise, or weight loss.
Why Lp(a) Matters
Lp(a) is now recognized as an independent, causal risk factor for atherosclerotic cardiovascular disease (heart attack and stroke) and for aortic valve stenosis (narrowing of the aortic heart valve) — on top of whatever risk your LDL, blood pressure, and other factors already carry. Someone with a normal LDL can still be at meaningfully higher cardiovascular risk if their Lp(a) is elevated.
Who Should Be Tested?
The most current U.S. lipid guidelines give Lp(a) testing a Class I recommendation — the strongest category — for every adult, at least once in their lifetime. Because Lp(a) is inherited in an autosomal dominant pattern (a 50% chance of passing it to each child), testing is especially important if you have:
- A personal or family history of early heart attack, stroke, or heart disease (before age 55 in men, 65 in women)
- A first-degree relative (parent, sibling, or child) with a known high Lp(a)
- Cardiovascular disease that seems out of proportion to your other risk factors
- Family history of aortic valve disease
💡 One test is usually enough. Because Lp(a) is genetically set and stays fairly stable throughout adult life, most people only need to have it checked once — it does not need to be rechecked yearly like a standard lipid panel.
Understanding Your Results
Lp(a) can be reported in two different units, which sometimes causes confusion:
| Level | What it means |
|---|---|
| Below 125 nmol/L (roughly 50 mg/dL) | Average range — Lp(a) is not adding meaningfully to your cardiovascular risk |
| 125–250 nmol/L (roughly 50–100 mg/dL) | Elevated — associated with about a 1.4-fold increase in long-term cardiovascular risk |
| Above 250 nmol/L | High — associated with at least a 2-fold increase in risk |
| 300–400 nmol/L or higher | Very high — risk becomes comparable to that of heterozygous familial hypercholesterolemia |
Labs sometimes report results in mg/dL and sometimes in nmol/L, and the two units don't convert with a simple multiplier because Lp(a) particles vary in size between people. Ask your provider to interpret your specific result rather than comparing raw numbers across different lab reports.
Can Lp(a) Be Lowered?
This is the most important thing to understand about Lp(a) today: there is currently no medication specifically approved to lower Lp(a). Because of this, the guideline-recommended approach is to aggressively manage everything else that contributes to your overall cardiovascular risk:
- Get LDL cholesterol to goal — usually with a statin, and often an additional agent such as Repatha or Lipfendra if needed
- Control blood pressure to target
- Don't smoke — and quit if you do
- Manage diabetes and other metabolic risk factors
- PCSK9 inhibitors (like Repatha or Lipfendra) modestly lower Lp(a) by about 20–30% as a side effect of their main LDL-lowering action, though this isn't why they're prescribed
- Niacin can lower Lp(a) but has not been shown to reduce cardiovascular events and is generally not recommended for this purpose
- Lipoprotein apheresis (a blood-filtering procedure) is reserved for a small number of very high-risk patients with extremely elevated Lp(a) and progressive cardiovascular disease
New Lp(a)-Lowering Drugs in Development
Several medications designed specifically to lower Lp(a) are in late-stage clinical trials, though none are FDA-approved yet. The field has moved from asking "can we lower Lp(a)?" (yes, dramatically) to "does lowering it actually prevent heart attacks and strokes?" — a question only large outcome trials can answer.
| Drug | Type | Status |
|---|---|---|
| Pelacarsen | Antisense oligonucleotide (injection) | Phase 3 outcomes trial completed follow-up in 2026; results pending |
| Olpasiran | siRNA (injection) | Phase 3 outcomes trials ongoing |
| Lepodisiran | Long-acting siRNA (injection) | Large Phase 3 outcomes trial ongoing |
| Zerlasiran | siRNA (injection) | Phase 3-ready |
| Muvalaplin | Oral small molecule (daily pill) | Phase 3 outcomes trial enrolling |
All of these reduced Lp(a) by 80–95%+ in earlier-phase trials — a dramatic effect on the number itself. Whether that translates into fewer heart attacks and strokes is what the ongoing outcome trials are designed to answer, and none of these medications are available to prescribe today.
Key Takeaways
- Lp(a) is a genetically determined, independent risk factor for heart attack, stroke, and aortic valve disease
- Current guidelines recommend every adult be tested at least once in their lifetime
- Levels are not meaningfully changed by diet, exercise, or weight loss
- A level above 125 nmol/L (~50 mg/dL) is considered elevated; above 250 nmol/L is high
- There is no FDA-approved medication to specifically lower Lp(a) yet — several are in Phase 3 trials
- Until a targeted therapy is proven and approved, management means aggressively controlling every other cardiovascular risk factor
- Because it's inherited, an elevated result is worth sharing with first-degree relatives
Our Team Can Help
All five of our providers diagnose and manage endocrine conditions. Book with any member of our team:
Book an Appointment → or call 832-968-7003